Market Overview

Piper Jaffray Reiterates Overweight Rating on Impax Labs

According to Piper Jaffray, Impax Laboratories (NASDAQ: IPXL) Overweight rating is reiterated.

Piper Jaffray said that it met with Impax senior management yesterday, and came away with increased confidence that management is tracking to a timely resolution of the manufacturing issues at its Hayward, CA facility (i.e., before March 1). “We reiterate our Overweight rating and $32 price target.”

Impax Laboratories closed yesterday at $19.92.

Posted-In: Piper JaffrayAnalyst Color Reiteration Analyst Ratings

 

Most Popular

Related Articles (IPXL)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters